NASDAQ:ARNA - Arena Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $95.33
  • Forecasted Upside: 39.91 %
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 15 Buy Ratings
  • 0 Strong Buy Ratings
$68.14
▲ +1.1 (1.64%)

This chart shows the closing price for ARNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arena Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARNA

Analyst Price Target is $95.33
▲ +39.91% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Arena Pharmaceuticals in the last 3 months. The average price target is $95.33, with a high forecast of $120.00 and a low forecast of $70.00. The average price target represents a 39.91% upside from the last price of $68.14.

This chart shows the closing price for ARNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 15 investment analysts is to buy stock in Arena Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/30/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/29/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/27/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/24/2021
  • 0 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2021The Goldman Sachs GroupInitiated CoverageBuy$90.00Medium
5/7/2021SVB LeerinkBoost Price TargetOutperform$90.00 ➝ $112.00High
4/27/2021CitigroupInitiated CoverageBuy$104.00Low
4/27/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated CoverageBuy$104.00Medium
4/15/2021Needham & Company LLCReiterated RatingBuyLow
4/13/2021Credit Suisse GroupBoost Price TargetOutperform$87.00 ➝ $102.00Medium
3/26/2021HC WainwrightBoost Price TargetBuy$90.00 ➝ $120.00Low
3/3/2021Cantor FitzgeraldLower Price TargetPositive ➝ Overweight$106.00 ➝ $100.00High
3/3/2021JonestradingLower Price TargetAverage ➝ Buy$101.00 ➝ $94.00High
2/25/2021SVB LeerinkLower Price TargetOutperform$92.00 ➝ $90.00Low
1/28/2021JonestradingInitiated CoverageBuyHigh
11/19/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated CoverageOutperform$100.00Low
11/19/2020Smith Barney CitigroupInitiated CoverageOutperform$100.00Medium
11/10/2020GuggenheimLower Price TargetBuy$115.00 ➝ $105.00High
11/10/2020Royal Bank of CanadaLower Price TargetPositive ➝ Outperform$80.00 ➝ $76.00High
11/10/2020SVB LeerinkBoost Price TargetOutperform$91.00 ➝ $92.00High
11/2/2020JPMorgan Chase & Co.Boost Price Target$71.00 ➝ $90.00Medium
10/13/2020Cantor FitzgeraldBoost Price Target$88.00 ➝ $110.00Low
9/30/2020Bank of AmericaBoost Price TargetBuy$75.00 ➝ $85.00Medium
9/18/2020CitigroupBoost Price TargetBuy$83.00 ➝ $120.00Medium
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightHigh
8/17/2020GuggenheimBoost Price TargetBuy$95.00 ➝ $115.00Low
8/6/2020HC WainwrightReiterated RatingBuy$90.00High
8/6/2020Wells Fargo & CompanyBoost Price TargetOverweight$60.00 ➝ $78.00Low
8/6/2020SVB LeerinkBoost Price TargetOutperform$73.00 ➝ $91.00Low
8/6/2020Needham & Company LLCReiterated RatingBuy$70.00Low
7/27/2020CitigroupBoost Price TargetBuy$65.00 ➝ $83.00Medium
6/29/2020HC WainwrightInitiated CoverageBuy$90.00High
6/2/2020Credit Suisse GroupBoost Price TargetPositive ➝ Outperform$77.00 ➝ $87.00Medium
5/18/2020Jefferies Financial GroupInitiated CoverageBuy$62.00High
5/8/2020Cantor FitzgeraldReiterated RatingBuy$56.00 ➝ $68.00Low
4/14/2020Needham & Company LLCReiterated RatingBuy$70.00High
3/31/2020GuggenheimInitiated CoverageBuy$95.00Low
3/26/2020Bank of AmericaUpgradeNeutral ➝ Buy$47.00 ➝ $56.00High
2/27/2020Cantor FitzgeraldReiterated RatingOverweight$62.00 ➝ $56.00High
1/31/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$58.00High
1/27/2020Royal Bank of CanadaReiterated RatingBuy$83.00Medium
11/14/2019Wood & CompanyReiterated RatingSellMedium
11/13/2019Bank of AmericaInitiated CoverageNeutral$51.00Low
8/11/2019Royal Bank of CanadaReiterated RatingBuy$79.00High
5/8/2019Cantor FitzgeraldReiterated RatingBuyHigh
4/3/2019Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$63.00 ➝ $77.00High
2/26/2019Cantor FitzgeraldReiterated RatingBuy$62.00High
1/28/2019Cantor FitzgeraldReiterated RatingBuy$62.00Low
12/13/2018Berenberg BankInitiated CoverageBuy ➝ Buy$55.00Low
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
11/19/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$56.00 ➝ $61.00Low
11/16/2018Royal Bank of CanadaBoost Price TargetOutperform$70.00Low
11/15/2018Needham & Company LLCSet Price TargetBuy$60.00High
11/15/2018Cantor FitzgeraldSet Price TargetBuy$65.00Low
11/7/2018Cantor FitzgeraldReiterated RatingBuy$65.00High
9/24/2018Cantor FitzgeraldSet Price TargetBuy$65.00High
8/7/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$58.00 ➝ $56.00High
5/31/2018Royal Bank of CanadaInitiated CoverageOutperform$65.00Medium
3/21/2018CitigroupReiterated RatingPositive ➝ Buy$62.00High
3/20/2018JMP SecuritiesBoost Price TargetMkt Outperform ➝ Outperform$63.00 ➝ $79.00High
3/20/2018Wells Fargo & CompanyLower Price TargetPositive ➝ Outperform$53.00 ➝ $60.00High
3/20/2018Needham & Company LLCUpgradeHold ➝ Buy$30.89 ➝ $60.00High
3/14/2018Needham & Company LLCReiterated RatingHoldHigh
2/27/2018CitigroupBoost Price TargetBuy ➝ Buy$37.00 ➝ $55.00High
2/20/2018JMP SecuritiesBoost Price TargetOutperform$36.00 ➝ $63.00Low
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$44.00Low
1/17/2018SVB LeerinkReiterated RatingOutperform ➝ Positive$53.00 ➝ $56.00Low
1/17/2018Cantor FitzgeraldReiterated RatingBuy$45.00Low
1/3/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
9/25/2017Cantor FitzgeraldReiterated RatingBuy$37.00High
8/8/2017Needham & Company LLCReiterated RatingHoldMedium
7/17/2017Cantor FitzgeraldReiterated RatingOverweight$37.00Low
7/12/2017Wells Fargo & CompanyReiterated RatingMarket Perform$15.00 ➝ $19.00Medium
7/11/2017CitigroupBoost Price TargetBuy ➝ Buy$23.00 ➝ $37.00Low
7/11/2017SVB LeerinkBoost Price TargetOutperform$47.00 ➝ $53.00High
7/7/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$27.00 ➝ $27.00High
6/30/2017Cantor FitzgeraldReiterated RatingOverweight$37.00Medium
6/27/2017CitigroupInitiated CoverageBuy ➝ Buy$23.00Medium
6/15/2017Cantor FitzgeraldReiterated RatingOverweightHigh
5/19/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$50.00High
3/16/2017(FBRC)Reiterated RatingOutperform$60.00Medium
1/23/2017(FBRC)Reiterated RatingOutperformN/A
1/7/2017Needham & Company LLCReiterated RatingHoldN/A
11/10/2016Needham & Company LLCReiterated RatingHoldN/A
11/9/2016(FBRC)Reiterated RatingBuy$60.00N/A
9/15/2016(FBRC)Initiated CoverageOutperform$60.00N/A
8/13/2016Needham & Company LLCReiterated RatingHoldN/A
8/10/2016Jefferies Financial GroupReiterated RatingBuyN/A
8/8/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
(Data available from 6/22/2016 forward)
Arena Pharmaceuticals logo
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.
Read More

Today's Range

Now: $68.14
Low: $66.27
High: $68.57

50 Day Range

MA: $64.26
Low: $60.48
High: $68.75

52 Week Range

Now: $68.14
Low: $59.55
High: $90.19

Volume

376,067 shs

Average Volume

479,361 shs

Market Capitalization

$4.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Arena Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Arena Pharmaceuticals in the last year: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, Guggenheim, HC Wainwright, Jonestrading, JPMorgan Chase & Co., Needham & Company LLC, Royal Bank of Canada, Smith Barney Citigroup, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for ARNA.

What is the current price target for Arena Pharmaceuticals?

15 Wall Street analysts have set twelve-month price targets for Arena Pharmaceuticals in the last year. Their average twelve-month price target is $95.33, suggesting a possible upside of 39.9%. HC Wainwright has the highest price target set, predicting ARNA will reach $120.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $70.00 for Arena Pharmaceuticals in the next year.
View the latest price targets for ARNA.

What is the current consensus analyst rating for Arena Pharmaceuticals?

Arena Pharmaceuticals currently has 15 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARNA will outperform the market and that investors should add to their positions of Arena Pharmaceuticals.
View the latest ratings for ARNA.

What other companies compete with Arena Pharmaceuticals?

How do I contact Arena Pharmaceuticals' investor relations team?

Arena Pharmaceuticals' physical mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company's listed phone number is 858-453-7200 and its investor relations email address is [email protected] The official website for Arena Pharmaceuticals is www.arenapharm.com.